Conversely, high SAMHD1 expression in Acute Myelogenous Leukaemia (AML) patients is associated with reduction in efficacy of the nucleoside-analogue anti-cancer drugs Cytarabine, Decitabine, Sapacitabine and Clofarabine29–33 as a result of SAMHD1 hydrolysis of their triphosphorylated forms34–36. This evidence concerns the gene SAMHD1 and cancer.